Clinical trials: Breast Cancer Nos Metastatic Recurrent
HER2-positive Recurrent or Metastatic Breast Cancer
A Study of JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Line Treatment for HER2-Positive Recurrent or Metastatic Breast Cancer
This study is a randomized, controlled, open-label, multicenter, phase II superiority clinical trial. The planned study population consists of participants with HER2-positive recurrent or metastatic breast cancer who have not…
- Trial name
- NCT07545044
- Testing
- JSKN003, Trastuzumab, Pertuzumab
- Volunteers
- 60 people
- Sponsor
- Shanghai JMT-Bio Inc.
Breast Cancer, Colorectal Cancer
Biological Therapy in Treating Patients With Metastatic Cancer
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. PURPOSE: Phase I trial to study the effectiveness of biological therapy in treating patients who have…
- Conditions
- Breast Cancer, Colorectal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer
- Trial name
- NCT00004604
- Testing
- CEA RNA-pulsed DC cancer vaccine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Duke University
Breast Cancer
Bevacizumab and Doxorubicin Hydrochloride Liposome in Treating Women With Locally Recurrent or Metastatic Breast Cancer
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00445406
- Testing
- bevacizumab + doxorubin hydrochloride liposme, Bevacizumab
- Where
- Switzerland
- Volunteers
- 43 people
- Sponsor
- Swiss Cancer Institute
Solid Tumors, Colorectal Cancer
A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
The main purpose of this 3-part study is to evaluate the safety and efficacy of the study drug known as LY2880070 in participants with advanced or metastatic solid tumors.
- Conditions
- Solid Tumors, Colorectal Cancer, Breast Cancer, Ovarian Cancer
- Trial name
- NCT02632448
- Testing
- LY2880070, Gemcitabine
- Where
- 16 sites in United States, Canada and 2 more
- Volunteers
- 229 people
- Sponsor
- Esperas Pharma Inc.
Malignant Neoplasm, Metastatic Malignant Neoplasm in the Brain
HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases
This phase I trial studies the side effects and best dose of HER2-CAR T cells in treating patients with cancer that has spread to the brain or leptomeninges and has come back (recurrent).
- Conditions
- Malignant Neoplasm, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Neoplasm in the Leptomeninges, Breast Cancer
- Trial name
- NCT03696030
- Testing
- Chimeric Antigen Receptor T-Cell Therapy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- City of Hope Medical Center
Breast Cancer
The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
This study aims to evaluate the efficacy and safety of TQB2102 for injection in HER2 negative recurrent/metastatic breast cancer.
- Trial name
- NCT06452706
- Testing
- TQB2102 for injection
- Where
- 16 sites in China
- Volunteers
- 42 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Breast Cancer
ABI-007 (Nab-Paclitaxel) and Gemcitabine in Treating Women With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as ABI-007(Nab-Paclitaxel((Nanoparticle Albumin Bound)-Paclitaxel)) and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping…
- Trial name
- NCT00110084
- Testing
- Gemcitabine, Paclitaxel protein-bound particles for injectable suspension (albumin-bound)
- Where
- 201 sites in United States
- Volunteers
- 50 people
- Sponsor
- Mayo Clinic
Estrogen Receptor Positive, Progesterone Receptor Positive
Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery
This phase I trial studies the side effects and best dose of alisertib when given together with fulvestrant in treating patients with hormone positive breast cancer that has spread to other parts of the body or has spread from…
- Conditions
- Estrogen Receptor Positive, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer
- Trial name
- NCT02219789
- Testing
- Alisertib, Fulvestrant, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Mayo Clinic
Triple Negative Breast Cancer, Non-small Cell Lung Cancer
A Biomarker Screening Protocol for Participants With Solid Tumors
Biomarker Screening Protocol for Preliminary Eligibility Determination for Adoptive T-cell Therapy Trials:This is a decentralized, multi-site, US-based biomarker screening study to identify participants who have specific disease…
- Conditions
- Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic
- Trial name
- START (NCT05891197)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Lyell Immunopharma, Inc.
Breast Cancer
Irofulven in Treating Patients With Metastatic Breast Cancer
Phase II trial to study the effectiveness of irofulven in treating patients who have metastatic breast cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00003796
- Testing
- irofulven
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Gene Therapy in Treating Women With Metastatic Breast Cancer
RATIONALE: Placing the gene for interleukin-12 into breast cancer cells may help the body build an immune response to kill tumor cells.
- Trial name
- NCT00849459
- Testing
- adenovirus-mediated human interleukin-12
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Max Sung
Breast Cancer
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Breast Cancer Progressing After First-Line Therapy With Avastin and Chemotherapy (TANIA)
This randomized, open-label, parallel-group study will assess the efficacy and s afety of Avastin (bevacizumab) in combination with chemotherapy versus chemother apy alone as second- and third-line therapy in patients with…
- Trial name
- NCT01250379
- Testing
- bevacizumab [Avastin], Chemotherapy
- Where
- 132 sites in Argentina, Austria and 11 more
- Volunteers
- 494 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
Phase II Study of Docetaxel +/- Nintedanib in Breast Cancer
National, randomized, unblinded, phase IIb trial with 2 strata: First-line chemotherapy / Second-line chemotherapy for locally recurrent or metastatic breast cancer.
- Trial name
- VAROCE (NCT01658462)
- Testing
- Docetaxel, Nintedanib, Docetaxel: increase of the dose
- Where
- 12 sites in France
- Volunteers
- 51 people
- Sponsor
- Centre Oscar Lambret
Metastatic Breast Cancer
A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus the Combination of Trastuzumab Plus Docetaxel in Patients With HER2-positive Breast Cancer
This is a Phase III, randomized, multicenter, multinational, two-arm, open-label clinical trial to investigate a first-line treatment of participants with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast…
- Trial name
- NCT02144012
- Testing
- Trastuzumab, Trastuzumab Emtansine, Docetaxel
- Where
- 8 sites in Malaysia, South Korea and 2 more
- Volunteers
- 49 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
PD-L1 Inhibitor + RT ± Ursodeoxycholic Acid in Recurrent/Metastatic HER2-Neg Breast Cancer
Experimental Group Adebrelimab (PD-L1 inhibitor) 1200 mg on Day 1, every 3 weeks. Radiotherapy (Stereotactic Body Radiation Therapy, SBRT) with a dose of 24 Gy/3 fractions within 3 weeks after the first immunotherapy dose.
- Trial name
- NCT06842472
- Testing
- Ursodeoxycholic Acid (URSO), Radiotherapy, Adebrelimab (PD-L1 inhibitor)
- Volunteers
- 70 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Breast Cancer
Mitoxantrone With or Without Docetaxel in Treating Women With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if mitoxantrone is more effective with or without docetaxel.
- Trial name
- NCT00002544
- Testing
- docetaxel, mitoxantrone hydrochloride
- Where
- Germany
- Volunteers
- 300 people
- Sponsor
- Arbeitsgemeinschaft fur Internistische Onkologie
Recurrent Breast Cancer, Stage IIIB Breast Cancer
Suramin and Paclitaxel in Treating Women With Stage IIIB-IV Breast Cancer
This phase I/II trial studies the best dose of suramin when given together with paclitaxel in treating women with stage IIIB-IV breast cancer.
- Conditions
- Recurrent Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer
- Trial name
- NCT00054028
- Testing
- suramin, paclitaxel, pharmacological study
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Breast Cancer
A Study of LY2523355 in Participants With Breast Cancer
The purpose of the study is to evaluate the anti-tumor activity of LY2523355 relative to ixabepilone for the treatment of metastatic or locally recurrent breast cancer using change in tumor size as a continuous measure of…
- Trial name
- NCT01416389
- Testing
- LY2523355, ixabepilone, pegfilgrastim
- Where
- 12 sites in United States
- Volunteers
- 39 people
- Sponsor
- Eli Lilly and Company
Melanoma, Merkel Cell Carcinoma
REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies
Patients received intratumoral (IT) injections of NKTR-262 in 3-week cycles for up to 3 cycles; bempegaldesleukin with or without nivolumab was administered every 3 weeks (q3w), and treatment continued until unacceptable…
- Conditions
- Melanoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- REVEAL (NCT03435640)
- Testing
- NKTR-262, bempegaldesleukin, nivolumab
- Where
- 14 sites in United States
- Volunteers
- 64 people
- Sponsor
- Nektar Therapeutics
Solid Tumors
Phase I Study of MT110 in Lung Cancer (Adenocarcinoma and Small Cell), Gastric Cancer or Adenocarcinoma of the Gastro-Esophageal Junction, Colorectal Cancer, Breast Cancer, Hormone-Refractory Prostate Cancer, and Ovarian Cancer
This phase I dose escalation study is intended to define the safety, tolerability and maximal tolerable dose (MTD) of MT110 in patients with advanced solid tumors.
- Trial name
- MT110-101 (NCT00635596)
- Testing
- MT110
- Where
- 4 sites in Germany
- Volunteers
- 65 people
- Sponsor
- Amgen Research (Munich) GmbH